HopeStage
Back to all studies
CompletedNCT02684279

Longer-Term Dasotraline for Binge Eating

About this title

Dasotraline Binge Eating Disorder Extension Study

Read the official source — NCT02684279
Medication studyAges 18–56United StatesEating disorders
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 56 years.

Listed locations
Phoenix and 56 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: February 29, 2016
Recruitment status
Completed
Enrollment listed in the registry
533
Sponsor
Sumitomo Pharma America, Inc.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 18 Years to 56 Years
Official registry ID
NCT02684279
Official title
Show the full official title

An Open-label, Flexibly-dosed, Multicenter, Extension Study of Dasotraline to Evaluate Long-term Safety and Tolerability in Adults With Binge-eating Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Phoenix · Beverly Hills · Encino

52 more locations
  • Garden Grove
  • Newport Beach
  • San Marcos
  • Santa Ana
  • Colorado Springs
  • Denver
  • Cromwell
  • Fort Myers
  • Jacksonville
  • North Miami
  • Orlando
  • South Miami
  • Alpharetta
  • Atlanta
  • Marietta
  • Libertyville
  • Indianapolis
  • Prairie Village
  • Wichita
  • Belmont
  • Boston
  • Methuen
  • Watertown
  • Saint Charles
  • Portsmouth
  • Cherry Hill
  • Princeton
  • Mount Kisco
  • New York
  • Raleigh
  • Akron
  • Cincinnati
  • Dayton
  • Mason
  • Oklahoma City
  • Medford
  • Portland
  • Salem
  • Allentown
  • Anderson
  • Greer
  • Mt. Pleasant
  • Memphis
  • Nashville
  • Austin
  • Houston
  • Plano
  • San Antonio
  • Murray
  • Woodstock
  • Herndon
  • Seattle

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Sumitomo Pharma America, Inc., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Dasotraline.

Who was this study for?

Listed age limits: 18 years to 56 years.

Want to explore more studies?

Explore studies